SCHEMBL1157710

SCHEMBL1157710

COCCOc1cc(N(Cc2cccnc2)c2cccc(C(=O)O)c2)ccc1OC

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.47
PDE4A P27815 4/20 0.46
PDE4B Q07343 4/20 0.46
PDE4C Q08493 4/20 0.46
PDE4D Q08499 4/20 0.46
ALDH1A1 P00352 3/20 0.45
NPSR1 Q6W5P4 2/20 0.45
USP2 O75604 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
GRM2 Q14416 2/20 0.43
MRGPRX4 Q96LA9 1/20 0.42
SMPD1 P17405 1/20 0.42
QPCT Q16769 2/20 0.41
MAPK1 P28482 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
TSHR P16473 1/20 0.41
BLM P54132 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4190639 0.93 GRM2 (0.48) MAPTPDE4APDE4BPDE4CPDE4D
SCHEMBL4190655 0.91 ALDH1A1 (0.50) MAPTPDE4APDE4BPDE4CPDE4D
SCHEMBL1157689 0.91 ALDH1A1 (0.43) MAPTPDE4APDE4BPDE4CPDE4D
SCHEMBL4186765 0.91 GRM2 (0.47) MAPTPDE4APDE4BPDE4CPDE4D
SCHEMBL1157339 0.89 MAPT (0.42) MAPTPDE4APDE4BPDE4CPDE4D
SCHEMBL4196225 0.89 LTC4S (0.45) MAPTPDE4APDE4BPDE4CPDE4D
SCHEMBL1157487 0.88 PDE4A (0.49) MAPTPDE4APDE4BPDE4CPDE4D
SCHEMBL1157933 0.88 PDE4A (0.46) MAPTPDE4APDE4BPDE4CPDE4D
SCHEMBL1157323 0.87 PDE4A (0.49) MAPTPDE4APDE4BPDE4CPDE4D
SCHEMBL3129016 0.87 TSHR (0.50) MAPTPDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046146-A9 Phosphodiesterase 4 inhibitors SCHUMACHER RICHARD A 2011-02-24 US claimed
US-7205320-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2007-04-17 US claimed
US-20070078139-A1 Phosphodiesterase 4 inhibitors SCHUMACHER RICHARD A 2007-04-05 US claimed
US-20040230072-A1 Phosphodiesterase 4 inhibitors SCHUMACHER RICHARD A (US) 2004-11-18 US claimed
EP-1353907-A2 PHOSPHODIESTERASE 4 INHIBITORS Memory Pharmaceutical Corporation (US) 2003-10-22 EP claimed
US-20030149052-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. 2003-08-07 US claimed
US-20020151566-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2002-10-17 US claimed
WO-2002074726-A2 ANILINE DERIVATIVES USEFUL AS PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2002-09-26 WO claimed
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS SCHUMACHER RICHARD A 2009-02-19 US disclosed
US-7405230-B2 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs MEMORY PHARMACEUTICALS CORPORATION (US) 2008-07-29 US disclosed
US-7205320-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2007-04-17 US disclosed
US-20050119225-A1 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs MEMORY PHARMACEUTICALS CORP. (US) 2005-06-02 US disclosed
US-20040230072-A1 Phosphodiesterase 4 inhibitors SCHUMACHER RICHARD A (US) 2004-11-18 US disclosed
US-6699890-B2 N-SUBSTITUTED DIETHER ANILINE AND DIETHER DIPHENYLAMINE DERIVATIVES MEMORY PHARMACEUTICALS CORP. 2004-03-02 US disclosed
EP-1353907-A2 PHOSPHODIESTERASE 4 INHIBITORS Memory Pharmaceutical Corporation (US) 2003-10-22 EP disclosed
US-20030149052-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. 2003-08-07 US disclosed
US-20020151566-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2002-10-17 US disclosed
WO-2002074726-A2 ANILINE DERIVATIVES USEFUL AS PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149052-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3A MAPT 4439/4885PDE4A 1/4885PDE4B 2/4885
US-20020151566-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3A MAPT 4439/4885PDE4A 1/4885PDE4B 2/4885
US-20040230072-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3A MAPT 4439/4885PDE4A 1/4885PDE4B 2/4885
US-20110046146-A9 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3B MAPT 4102/4885PDE4A 1/4885PDE4B 2/4885
US-20070078139-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3B MAPT 4102/4885PDE4A 1/4885PDE4B 2/4885
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS PDE4A, PDE4B, PDE3A MAPT 3913/4885PDE4A 1/4885PDE4B 2/4885
US-20050119225-A1 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs PDE4A, PDE4B, PDE3A MAPT 3913/4885PDE4A 1/4885PDE4B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.